Goldman Sachs Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $42
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Corinne Jenkins has reaffirmed a Buy rating on Rhythm Pharmaceuticals (NASDAQ:RYTM) and increased the price target from $38 to $42.
December 07, 2023 | 2:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Goldman Sachs analyst Corinne Jenkins maintains a Buy rating on Rhythm Pharmaceuticals and raises the price target from $38 to $42.
The increase in price target by a reputable investment bank like Goldman Sachs typically signals a positive outlook on the company's future performance, which can lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100